About GLP-1 Picks

Independent research in a $50B market.

GLP-1 Picks exists because the telehealth GLP-1 market is loud, confusing, and full of paid recommendations dressed up as reviews. We rank 53 providers by a fixed methodology, and we publish how we do it.

Our Mission

Help the millions of Americans navigating GLP-1 medications find a program that fits their budget, clinical needs, and safety standards, without hidden fees, intro-rate bait, or a score you can't trust.

The GLP-1 market is projected to hit $133B by 2035. That much money attracts a lot of bad actors. Our job is to tell you which providers are worth your money and which are not, using the same methodology for all 53.

How we're different

Scores you can't buy

No provider can pay to change its score. Our scoring is based on a fixed, published methodology:

Pricing (25%)
Clinical oversight (25%)
Medication options (20%)
User experience (15%)
Transparency (15%)

We group the rankings into our affiliate partners and the other providers we rank: affiliate status only decides which group a provider appears in, never its score, and within each group providers are ordered by that score.

Separately, the picks we feature for an easy start (our Top Pick and top-3) are chosen from our affiliate partners and may prioritize the ones with stronger affiliate economics; we label those as featured and earn a commission on them.

Affiliate partnerships exist and we disclose them openly, but they never move a score.

Prices we verify ourselves

Every price shown on this site was checked against the provider's live website in the last 30 days. No cached pricing, no pre-promotion intro rates, no "starting at" numbers that jump 2-3x after month one. If a provider changes their pricing, we update our ranking the same week.

Independent, not a pharma front

We don't take money from drug manufacturers, pharmacies, or compounding labs. We don't run sponsored content. Our only revenue is affiliate commissions when a reader chooses a provider we recommend and signs up. That means our incentive aligns with yours: recommend good providers so you actually use them, not ones who paid the most.

What we cover

53 telehealth providers

Independent reviews of every major GLP-1 telehealth platform, with scores, pricing, pros/cons, and detailed analysis.

1,378 provider comparisons

Side-by-side comparisons of every provider pair, pricing, medications, clinical oversight, insurance.

All 50 states + DC

Medicaid coverage, regulatory landscape, and top providers for every state.

FDA safety tracking

Active monitoring of FDA warning letters, compounding enforcement, and provider safety flags.

Pipeline drugs

Retatrutide, orforglipron, Foundayo, and what's coming next, with source-cited timelines.

Medicare GLP-1 Bridge

Eligibility, pricing, and prep for the July 2026 Medicare Part D launch.

Editorial principles

Independence. Scoring by fixed methodology. Never by affiliate status.

Transparency. The methodology is public and auditable. Affiliate partnerships are disclosed on every page with an affiliate link.

Accuracy. Prices verified monthly. Clinical claims tied to published trial data or FDA sources.

Consumer-first. When our interests diverge from a provider's, we side with the reader. Corrections happen immediately, even when they cost us a partner.

Completeness. We cover all 42 major providers, not just the ones who pay us. If a reader would want to know about it, we publish it.

Read the full editorial policy →

Who's behind GLP-1 Picks

Founder & Editor

Iacob Pastina

Independent technology researcher and publisher. Builds comparison sites through methodical research across pricing, clinical oversight, regulatory signals, and user outcomes. Not a medical professional, every clinical claim on this site links to primary sources (NEJM, FDA, CMS, manufacturer trial data).

Iacob personally verifies every provider ranking and writes or edits every article on the site. GLP-1 Picks is independently operated, no investors, no pharmaceutical or telehealth parent company.

A note on medical expertise:GLP-1 Picks is a comparison and research site, not a medical provider. We cite clinical trial data, FDA sources, and peer-reviewed research, but we are not doctors and do not provide medical advice. Every article includes a disclaimer to consult a licensed healthcare provider before starting any GLP-1 medication. We are actively seeking a named medical reviewer (MD or DO specializing in obesity medicine) to review YMYL content; if that's you, reach out.

Get in touch

Tips, corrections, or errors in our data: editor@glp1picks.com. We take corrections seriously, if we got a price wrong, a score wrong, or misstated a clinical fact, we want to know.

Provider partnerships:We review every provider on the same methodology regardless of partnership status. If you're a provider interested in an affiliate partnership, email the same address.

Press & media: Same inbox. We respond to every email from a verified journalist within 2 business days.

Reader questions: For help choosing a provider, the match quizis faster than email. If you've used it and still want a human opinion, the inbox is open.